Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is a complex biological process and is often diagnosed at advanced stages with no effective treatment options. With advances in tumor biology and molecular genetic profiling, several different signaling pathways and molecular mechanisms have been identified as responsible for initiating and promoting HCC. Targeting these critical pathways, which include the receptor tyrosine kinase pathways, the Ras mitogen-activated protein kinase (Ras/Raf/MAPK), the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), the Wnt/β-catenin signaling pathway, the ubiquitin/proteasome degradation and the hedgehog signaling pathway has led to the identification of novel therapeutics for HCC treatment. In this review, we elaborated on our current understanding of the signaling pathways involved in the development and initiation of HCC and anticipate the potential targets for therapeutic drug development.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Understanding how molecular signaling pathways lead to physiological or pathophysiological changes has long been a key way of identifying therapies for diseases including cancer and diabetes.
“Understanding how molecular signaling pathways lead to physiological or pathophysiological changes has long been a key way of identifying therapies for diseases including cancer 232 , 233 and diabetes.”
From The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments (2022) · cites this paper as [232]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · see citing works
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974 · see citing works
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · see citing works
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,606 · see citing works
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,019 · see citing works
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · see citing works
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B. D., Terrian, D. M., Milella, M., Tafuri, A., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,285 · see citing works
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858 · see citing works
Caught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482 · see citing works
Hepatocellular carcinoma: a global view
Yang, J.-D., & Roberts, L. (2010) · Nature Reviews Gastroenterology &Hepatology · doi:10.1038/nrgastro.2010.100 · Cited by 1,320 · see citing works
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258 · see citing works
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
Berman, D. M., Karhadkar, S. S., Maitra, A., Oca, R. M. D., Gerstenblith, M. R., Briggs, K. J., Parker, A. R., Shimada, Y., Eshleman, J. R., Watkins, D. N., et al. (2003) · Nature · doi:10.1038/nature01972 · Cited by 1,251 · see citing works
Epidemiology of Hepatocellular Carcinoma
Mittal, S., & El‐Serag, H. B. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182872f29 · Cited by 1,078 · see citing works
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 879 · see citing works
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872 · see citing works
Budhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L., Tang, Z., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 843 · see citing works
SOCS Proteins: Negative Regulators of Cytokine Signaling
Krebs, D. L., & Hilton, D. J. (2001) · Stem Cells · doi:10.1634/stemcells.19-5-378 · Cited by 826 · see citing works
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S. R., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 824 · see citing works
Cheng, A., Kang, Y., Lin, D., Park, J., Kudo, M., Qin, S., Chung, H. C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777 · see citing works
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G. R., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 774 · see citing works
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772 · see citing works
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S. N., Alsinet, C., Tovar, V., Roayaie, S., Mínguez, B., Solé, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 734 · see citing works
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 722 · see citing works
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710 · see citing works
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20513 · Cited by 699 · see citing works
Emerging Multipotent Aspects of Hepatocyte Growth Factor
Matsumoto, K., & Nakamura, T. (1996) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021283 · Cited by 666 · see citing works
Ormandy, L. A., Hillemann, T., Wedemeyer, H. H., Manns, M. P., Greten, T. F., & Korangy, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3232 · Cited by 643 · see citing works
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 639 · see citing works
Llovet, J. M., Decaens, T., Raoul, J., Boucher, É., Kudo, M., Chang, C., Kang, Y., Assénat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 595 · see citing works
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Zhu, A. X., Kudo, M., Assénat, E., Cattan, S., Kang, Y., Lim, H. Y., Poon, R. T. P., Blanc, J., Vogel, A., Chen, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568 · see citing works
Expression of Yes-associated protein in common solid tumors
Steinhardt, A. A., Gayyed, M. F., Klein, A. P., Dong, J., Maitra, A., Pan, D., Montgomery, E. A., & Anders, R. A. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.04.012 · Cited by 552 · see citing works
Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Laethem, J. V., Vlierberghe, H. V., Trojan, J., Kolligs, F. T., Weiss, A. A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 552 · see citing works
The changing pattern of epidemiology in hepatocellular carcinoma
Nordenstedt, H., White, D. L., & El‐Serag, H. B. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60507-5 · Cited by 536 · see citing works
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaPreprint
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 524 · see citing works
Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase
Zhang, Y. E., Chang, C., Gehling, D. J., Hemmati‐Brivanlou, A., & Derynck, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.974 · Cited by 523 · see citing works
Siegel, A. B., Cohen, E. I., Ocean, A. J., Lehrer, D., Goldenberg, A. S., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A. D., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 505 · see citing works
Shi, F., Shi, M., Zeng, Z., Qi, R., Liu, Z., Zhang, J., Yang, Y., Tien, P., & Wang, F. (2010) · International Journal of Cancer · doi:10.1002/ijc.25397 · Cited by 466 · see citing works
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J. P., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T. R., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462 · see citing works
Chang, Y. S., Adnane, J., Trail, P. A., Levy, J. B., Henderson, A. J., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0393-4 · Cited by 459 · see citing works
Inhibitors of Cytokine Signal Transduction
Wormald, S., & Hilton, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r300030200 · Cited by 440 · see citing works
Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000000965 · Cited by 433 · see citing works
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 423 · see citing works
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 397 · see citing works
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prìeto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 384 · see citing works
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G. H., & Torbenson, M. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0941 · Cited by 382 · see citing works
Wu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380 · see citing works
Angiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 371 · see citing works
Gollob, J., Wilhelm, S. A., CARTER, C., & Kelley, S. K. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360 · see citing works
Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
Gandhi, T. K. B., & Hong, W. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00049 · Cited by 349 · see citing works
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., 植木, 孝., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 348 · see citing works
Dimitroulis, D., Damaskos, C., Valsami, S. I., Davakis, S., Garmpis, N., Spartalis, E. D., Athanasiou, A., Moris, D., Sakellariou, S., Kykalos, S., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i29.5282 · Cited by 330 · see citing works
Hui, L., Zatloukal, K., Scheuch, H., Stępniak-Konieczna, E., & Wagner, E. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37156 · Cited by 308 · see citing works
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289 · see citing works
Huynh, H. T., Nguyen, T. T. T., Chow, P. K. H., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289 · see citing works
Dong, Y., Hakimi, M., Chen, X., Kumaraswamy, E., Cooch, N. S., Godwin, A. K., & Shiekhattar, R. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00424-6 · Cited by 274 · see citing works
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis
Sicklick, J. K., Li, Y.-X., Jayaraman, A., Kannangai, R., Qi, Y. P., Vivekanandan, P., Ludlow, J. W., Owzar, K., Chen, W., Torbenson, M. S., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi292 · Cited by 270 · see citing works
Activation of the hedgehog pathway in human hepatocellular carcinomas
Huang, S., He, J., Zhang, X., Bian, Y., Yang, L., Xie, G., Zhang, K., Tang, W. W., Stelter, A. A., Wang, Q., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi378 · Cited by 244 · see citing works
Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma
Song, W., Li, H., Tao, K., Li, R., Song, Z. Q., Zhao, Q., Zhang, F., & Dou, K. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01777.x · Cited by 228 · see citing works
Poon, R. T. P., Ho, J. W., Tong, C. S. W., et al. (2004) · British journal of surgery · doi:10.1002/bjs.4594 · Cited by 228 · see citing works
植木, 孝., Fujimoto, J., Suzuki, T., Yamamoto, H., & Okamoto, E. (1997) · Hepatology · doi:10.1002/hep.510250413 · Cited by 225 · see citing works
Semela, D., Piguet, A., Kolev, M., Schmitter, K., Hlushchuk, R., Djonov, V., Stoupis, C. A., & Dufour, J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.021 · Cited by 225 · see citing works
The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications
Burger, A. M., & Seth, A. K. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.006 · Cited by 224 · see citing works
Brodowska, K., Al-Moujahed, A., Marmalidou, A., Meyer zu Horste, M., Cichy, J., Miller, J. W., Gragoudas, E., & Vavvas, D. G. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.04.011 · Cited by 220 · see citing works
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma
Yang, S., & Liu, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.5557 · Cited by 218 · see citing works
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Zhou, Q., Lui, V. W. Y., & Yeo, W. (2011) · Future Oncology · doi:10.2217/fon.11.95 · Cited by 210 · see citing works
Song, S., Xie, M., Scott, A. W., Jin, J., Ma, L., Dong, X., Skinner, H. D., Johnson, R. L., Ding, S., & Ajani, J. A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0560 · Cited by 200 · see citing works
Bum‐Erdene, K., Zhou, D., González-Gutiérrez, G., Ghozayel, M. K., Si, Y., Xu, D. D., Shannon, H. E., Bailey, B. J., Corson, T. W., Pollok, K. E., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.010 · Cited by 200 · see citing works
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances
Dhanasekaran, R., Bandoh, S., & Roberts, L. (2016) · F1000Research · doi:10.12688/f1000research.6946.1 · Cited by 199 · see citing works
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J. F., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba101 · Cited by 195 · see citing works
You, L., He, B., Xu, Z., Uematsu, K., Mazières, J., Fujii, N., Mikami, I., Reguart, N., McIntosh, J. K., Kashani–Sabet, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1227 · Cited by 194 · see citing works
Cariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M., Ullrich, A., & Bréchot, C. (1988) · PubMed · Cited by 193 · see citing works
Expression of hypoxia-inducible factor-1α in oligodendrogliomas
Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rössler, K., Prodinger, A., Budka, H., & Hainfellner, J. A. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1 · Cited by 192 · see citing works
Boon, E. M. J., Keller, J. J., Wormhoudt, T. A. M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601505 · Cited by 190 · see citing works
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.029 · Cited by 189 · see citing works
Won, C., Kim, B., Yi, E. H., Choi, K., Kim, E., Jeong, J., Lee, J. H., Jang, J., Yoon, J., Jeong, W., et al. (2015) · Hepatology · doi:10.1002/hep.27968 · Cited by 187 · see citing works
Hedgehog signal transduction: recent findings
Nybakken, K. E. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00333-7 · Cited by 184 · see citing works
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update
Liu, M., Jiang, L., & Guan, X. (2014) · Protein & Cell · doi:10.1007/s13238-014-0065-9 · Cited by 181 · see citing works
Regulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179 · see citing works
Höpfner, M., Sutter, A. P., Huether, A., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.024 · Cited by 173 · see citing works
Wnt/β-catenin signaling mediates oval cell response in rodents
Apte, U. M., Thompson, M. D., Cui, S., Liu, B., Cieply, B. W., & Monga, S. P. (2007) · Hepatology · doi:10.1002/hep.21973 · Cited by 173 · see citing works
Opportunities for Targeted Therapies in Hepatocellular Carcinoma
Thomas, M. B., & Abbruzzese, J. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1537 · Cited by 172 · see citing works
Ng, I. O., Poon, R. T. P., Lee, J. M. F., Fan, S. T., NG, M. M., & Tso, W. K. (2001) · American Journal of Clinical Pathology · doi:10.1309/fxnl-qtn1-94fh-ab3a · Cited by 162 · see citing works
Mohan, C. D., Bharathkumar, H., Bulusu, K. C., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601104 · Cited by 159 · see citing works
Hedgehog Signaling Pathway Regulates Autophagy in Human Hepatocellular Carcinoma Cells
Wang, Y., Han, C. L., Lu, L., et al. (2013) · Hepatology · doi:10.1002/hep.26394 · Cited by 156 · see citing works
Sieghart, W., Fuereder, T., Schmid, K., Cejka, D., Werzowa, J. M., Wrba, F., Wang, X., Gruber, D., Rasoul‐Rockenschaub, S., Peck‐Radosavljevic, M., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000252780.42104.95 · Cited by 154 · see citing works
Therapeutic Targeting of the JAK / STAT Pathway
Aittomäki, S., & Pesu, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12164 · Cited by 152 · see citing works
Novel therapeutic Strategies for Targeting Liver Cancer Stem Cells
Oishi, N., & Wang, X. W. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.517 · Cited by 145 · see citing works
Chen, C. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i15.1964 · Cited by 142 · see citing works
Ladu, S., Calvisi, D. F., Conner, E. A., Farina, M., Factor, V. M., & Thorgeirsson, S. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.012 · Cited by 129 · see citing works
Schirmacher, P., Held, W. A., Yang, D., et al. (1992) · PubMed · Cited by 123 · see citing works
Grabinski, N., Ewald, F., Hofmann, B. T., Staufer, K., Schumacher, U., Nashan, B., & Jücker, M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-85 · Cited by 122 · see citing works
Kim, Y., Yoon, J. W., Xiao, X., Dean, N. M., Monia, B. P., & Marcusson, E. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3040 · Cited by 121 · see citing works
Development of Hepatocellular Carcinoma in Iqgap2 -Deficient Mice Is IQGAP1 Dependent
Schmidt, V. A., Chiariello, C. S., Capilla, E., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01090-07 · Cited by 119 · see citing works
Toh, H. C., Chen, P., Carr, B. I., et al. (2012) · Cancer · doi:10.1002/cncr.27758 · Cited by 109 · see citing works
Dihlmann, S., Klein, S., & Mv, M. V. K. D. (2003) · PubMed · Cited by 108 · see citing works
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future
Zhang, X., Ng, H. L. H., Lü, A., Lin, C., Zhou, L., Lin, G., Zhang, Y., Yang, Z., & Zhang, H. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.381 · Cited by 107 · see citing works
Review of angiogenesis in hepatocellular carcinoma
Muto, J., Shirabe, K., Sugimachi, K., & Maehara, Y. (2014) · Hepatology Research · doi:10.1111/hepr.12310 · Cited by 95 · see citing works
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2
Lee, Y.-H., Seo, D., Choi, K., Andersen, J. B., Won, M.-A., Kitade, M., Gómez-Quiroz, L. E., Judge, A. D., Marquardt, J. U., Raggi, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3531 · Cited by 93 · see citing works
Farinati, F., Sergio, A., Baldan, A., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-33 · Cited by 92 · see citing works
Dimri, M., Humphries, A., Laknaur, A., Elattar, S., Lee, T. J., Sharma, A. K., Kolhe, R. B., & Ande, S. (2019) · Hepatology · doi:10.1002/hep.30818 · Cited by 91 · see citing works
Self-citationFeng, D. Y. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i1.33 · Cited by 90 · see citing works
Implication of the Hedgehog pathway in hepatocellular carcinoma
Corte, C. M. D., Viscardi, G., Papaccio, F., Esposito, G., Martini, G., Ciardiello, D., Martinelli, E., Ciardiello, F., & Morgillo, F. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i24.4330 · Cited by 90 · see citing works
The tumor secretory factor ZAG promotes white adipose tissue browning and energy wasting
Elattar, S., Dimri, M., & Ande, S. (2018) · The FASEB Journal · doi:10.1096/fj.201701465rr · Cited by 88 · see citing works
Self-citationOliveri, R. S., Wetterslev, J., & Gluud, C. N. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61285-9 · Cited by 85 · see citing works
The Hippo Pathway in Human Upper Gastrointestinal Dysplasia and Carcinoma: A Novel Oncogenic Pathway
Lam-Himlin, D. M., Daniels, J. A., Gayyed, M. F., Dong, J., Maitra, A., Pan, D., Montgomery, E. A., & Anders, R. A. (2007) · International Journal of Gastrointestinal Cancer · doi:10.1007/s12029-007-0010-8 · Cited by 84 · see citing works
Chuma, M., Terashita, K., & Sakamoto, N. (2014) · Hepatology Research · doi:10.1111/hepr.12459 · Cited by 82 · see citing works
Hepatocellular carcinoma development in cirrhosis
Okuda, H. (2007) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2006.07.002 · Cited by 82 · see citing works
Galuppo, R., Maynard, E. C., Shah, M. B., Daily, M. F., Chen, C., Spear, B. T., & Gedaly, R. (2014) · PubMed · Cited by 72 · see citing works
Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions
Choi, K., Baik, I. H., Ye, S., et al. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00231 · Cited by 67 · see citing works
Hedgehog Signaling Blockade Delays Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein
Arzumanyan, A. L., Sambandam, V., Clayton, M. M., Choi, S. S., Xie, G., Diehl, A. M., Yu, D., & Feitelson, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2329 · Cited by 65 · see citing works
Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis
Zhao, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7971 · Cited by 64 · see citing works
Dhar, D. K., Naora, H., Yamanoi, A., et al. (2002) · PubMed · Cited by 61 · see citing works
Hattori, E. (2003) · Hepatology Research · doi:10.1016/j.hepres.2003.07.002 · Cited by 60 · see citing works
Promising diagnostic and prognostic value of E2Fs in human hepatocellular carcinoma
Huang, Y., Ning, G., Chen, L., Lian, Y., Gu, Y., Wang, J., Chen, D., Wei, H. J., & Huang, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s182001 · Cited by 59 · see citing works
Shimamura, T., Saito, S., Morita, K., et al. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02201.x · Cited by 57 · see citing works
Yasuda, E., Kumada, T., Takai, S., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.273 · Cited by 54 · see citing works
Xu, Z., Hu, J., Cao, H., Pilo, M. G., Cigliano, A., Shao, Z., Xu, M. M., Ribback, S., Dombrowski, F., Calvisi, D. F., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.158 · Cited by 49 · see citing works
Lund, P., Schubert, D., Niketeghad, F., et al. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.10.018 · Cited by 47 · see citing works
Halaschek-Wiener, J., Wacheck, V., Kloog, Y., & Jansen, B. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.003 · Cited by 45 · see citing works
Hepatocellular carcinoma and the ubiquitin–proteasome system
Dawson, S. P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.003 · Cited by 45 · see citing works
Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?
Galuppo, R., Ramaiah, D., Ponte, O. M., & Gedaly, R. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3058-x · Cited by 45 · see citing works
Lee, T. K., Man, K., Ho, J. W., et al. (2004) · Carcinogenesis · doi:10.1093/carcin/bgi002 · Cited by 45 · see citing works
Sheng, X., Sun, X., Sun, K., Sui, H. X., Qin, J., & Li, Q. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3667 · Cited by 45 · see citing works
Koch, I., Baron, A., Roberts, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4134 · Cited by 38 · see citing works
Huether, A., Höpfner, M., Sutter, A. P., Baradari, V., Schuppan, D., & Scherübl, H. (2006) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v12.i32.5160 · Cited by 37 · see citing works
Lian, Z., Liu, J., Wu, M., et al. (2007) · Hepatology · doi:10.1002/hep.21610 · Cited by 35 · see citing works
Influence of limonin on Wnt signalling molecule in HepG2 cell lines
Kulanthaivel, L., Revathy, R., Vijayaprakash, S., et al. (2013) · Journal of Natural Science Biology and Medicine · doi:10.4103/0976-9668.107276 · Cited by 34 · see citing works
Hepatocellular carcinoma – Authors' reply
Forner, A., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61286-0 · Cited by 28 · see citing works
Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma
Wei, Z., Doria, C., & Liu, Y. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7633 · Cited by 28 · see citing works
The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action
Shi, X., Zhu, H., Liu, T., Shen, X., & Zhu, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.032 · Cited by 28 · see citing works
Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC).
Abou-Alfa, G. K., Gansukh, B., Chou, J. F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4043 · Cited by 25 · see citing works
Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma
Jeng, K., Jeng, C., Jeng, W., et al. (2015) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2015.03.001 · Cited by 24 · see citing works
Faivre, S. J., Fartoux, L., Bouattour, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.270 · Cited by 19 · see citing works
Dimri, M., Bilogan, C. K., Pierce, L. X., Naegele, G., Vasanji, A., Gibson, I., McClendon, A., Tae, K., & Sakaguchi, T. F. (2017) · Development · doi:10.1242/dev.147397 · Cited by 17 · see citing works
Self-citationXu, C., Liu, C., Huang, W., Tu, S., & Wan, F. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt006 · Cited by 16 · see citing works
Live or Let Die: E2F1 and PI3K Pathways Intersect to Make Life or Death Decisions
Dynlacht, B. D. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.017 · Cited by 15 · see citing works
Dimri, M., Joshi, J., Chakrabarti, R., et al. (2014) · Zebrafish · doi:10.1089/zeb.2014.0992 · Cited by 14 · see citing works
Self-citationTherapeutic approaches targeting tumor vasculature in gastrointestinal cancers
Takahashi, Y. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e268 · Cited by 9 · see citing works
Dimri, M., Joshi, J., Shrivastava, N., et al. (2015) · PubMed · Cited by 8 · see citing works
Self-citationLigand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists
Joshi, J., Dimri, M., Ghosh, S., et al. (2015) · Current Computer - Aided Drug Design · doi:10.2174/1573409911666150812130420 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Gajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89 · see citing works
Venkatesh, V. S., Grossmann, M., Zajac, J. D., & Davey, R. A. (2022) · Obesity Reviews · doi:10.1111/obr.13429 · Cited by 22 · see citing works
- Authors
- Dimri, M., & Satyanarayana, A.
- Affiliations
- Augusta University (US)
- Department of Biochemistry and Molecular Biology, Molecular Oncology & Biomarkers Program, Georgia Cancer Center, Augusta University, Room-CN3144, 1410 Laney Walker Blvd., Augusta, GA 30912, USA
- Corresponding author
- Dimri, Manali
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-02-20
- Volume
- 12
- Issue
- 2
- Pages
- 491
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7072513
- OpenAlex
- W3008957256
- Cited by
- 311
- References
- 143
- Citations by year
- 2026: 22 · 2025: 36 · 2024: 35 · 2023: 58 · 2022: 73 · 2021: 66 · 2020: 21
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP2DK105565)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatocellular carcinoma, signaling pathways, therapeutic target, receptor tyrosine kinase signaling, RAS/MAPK pathway, PI3K/AKT/mTOR pathway, Wnt/β-catenin signaling, ubiquitin-proteasome degradation, Hedgehog signaling, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
